Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. (original) (raw)

Research Article Free access | 10.1172/JCI118475

H A Magna, L M Reeves, L L Lopresti-Morrow, S A Yocum, P J Rosner, K F Geoghegan, and J E Hambor

Central Research Division, Pfizer Inc., Groton, Connecticut 06340, USA.

Find articles by Mitchell, P. in:PubMed |Google Scholar

Central Research Division, Pfizer Inc., Groton, Connecticut 06340, USA.

Find articles by Magna, H. in:PubMed |Google Scholar

Central Research Division, Pfizer Inc., Groton, Connecticut 06340, USA.

Find articles by Reeves, L. in:PubMed |Google Scholar

Central Research Division, Pfizer Inc., Groton, Connecticut 06340, USA.

Find articles by Lopresti-Morrow, L. in:PubMed |Google Scholar

Central Research Division, Pfizer Inc., Groton, Connecticut 06340, USA.

Find articles by Yocum, S. in:PubMed |Google Scholar

Central Research Division, Pfizer Inc., Groton, Connecticut 06340, USA.

Find articles by Rosner, P. in:PubMed |Google Scholar

Central Research Division, Pfizer Inc., Groton, Connecticut 06340, USA.

Find articles by Geoghegan, K. in:PubMed |Google Scholar

Central Research Division, Pfizer Inc., Groton, Connecticut 06340, USA.

Find articles by Hambor, J. in:PubMed |Google Scholar

Published February 1, 1996 -More info

Published February 1, 1996 -Version history

View PDF

Abstract

Proteolysis of triple-helical collagen is an important step in the progression toward irreversible tissue damage in osteoarthritis. Earlier work on the expression of enzymes in cartilage suggested that collagenase-1 (MMP-1) contributes to the process. Degenerate reverse transcription polymerase chain reaction experiments, Northern blot analysis, and direct immunodetection have now provided evidence that collagenase-3 (MMP-13), an enzyme recently cloned from human breast carcinoma, is expressed by chondrocytes in human osteoarthritic cartilage. Variable levels of MMP-13 and MMP-1 in cartilage was significantly induced at both the message and protein levels by interleukin-1 alpha. Recombinant MMP-13 cleaved type II collagen to give characteristic 3/4 and 1/4 fragments; however, MMP-13 turned over type II collagen at least 10 times faster than MMP-1. Experiments with intact type II collagen as well as a synthetic peptide suggested that MMP-13 cleaved type II collagen at the same bond as MMP-1, but this was then followed by a secondary cleavage that removed three amino acids from the 1/4 fragment amino terminus. The expression of MMP-13 in osteoarthritic cartilage and its activity against type II collagen suggest that the enzyme plays a significant role in cartilage collagen degradation, and must consequently form part of a complex target for proposed therapeutic interventions based on collagenase inhibition.

Version history